for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

CureVac BV

CVAC.O

Latest Trade

40.79USD

Change

0.00(0.00%)

Volume

766

Today's Range

--

 - 

--

52 Week Range

35.05

 - 

151.80

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Curevac Reports Revenue Of Eur 29.3 Mln and Eur 61.8 Mln For 3 and 9 Months Ended Sept 30

Nov 18 (Reuters) - Curevac Nv <5CV.DE>::CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER AND FIRST NINE MONTHS OF 2021 AND PROVIDES BUSINESS UPDATE.REVENUES AMOUNTED TO EUR 29.3 MILLION, EUR 61.8 MILLION FOR THREE,NINE MONTHS ENDED SEPT 30, 2021, RESPECTIVELY, INCREASE OF EUR 24.1 MILLION,EUR 19.0 MILLION.OPERATING LOSS AMOUNTED TO EUR 143.1 MILLION AND EUR 406.7 MILLION FOR THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2021.CASH POSITION OF EUR 1.06 BILLION AS OF SEPTEMBER 30, 2021.CONTINUES TO ASSESS SUPPLIER COMMITMENTS RELATED TO WITHDRAWAL OF FIRST-GENERATION COVID-19 VACCINE CANDIDATE.BASED ON COMMUNICATION FROM EMA IN OCTOBER 2021, CUREVAC ESTIMATED THAT EARLIEST POSSIBLE APPROVAL OF CVNCOV WOULD COME IN Q2 OF 2022.BY THIS TIME, CUREVAC AND GSK EXPECT CANDIDATES FROM SECOND-GENERATION VACCINE PROGRAM TO BE PROGRESSING THROUGH CLINICAL DEVELOPMENT.AS A DIRECT CONSEQUENCE OF WITHDRAWAL OF CVNCOV, EXISTING ADVANCED PURCHASE AGREEMENT WITH EUROPEAN COMMISSION WILL CEASE.

CureVac Presents Data From Phase 1 Study Of Oncology Candidate Cv8102

Nov 10 (Reuters) - CUREVAC NV <5CV.DE>::PRESENTS PROMISING DATA AT SITC FROM PHASE 1 STUDY OF ONCOLOGY CANDIDATE CV8102 SHOWING SYSTEMIC IMMUNE RESPONSE.EXPANSION PART OF PHASE 1 STUDY FULLY RECRUITED; RESULTS EXPECTED IN SECOND HALF OF 2022.IMMUNE PROFILING OF CLINICAL TRIAL PARTICIPANTS IN PHASE 1 DOSE-ESCALATION STUDY SHOWS IMMUNE RESPONSE IN BOTH INJECTED AND NON-INJECTED LESIONS.

German Economy Ministry Says Government To Retain Curevac Holding

Oct 18 (Reuters) - GERMAN ECONOMY MINISTRY SPOKESPERSON::GOVERNMENT WILL RETAIN A HOLDING IN CUREVAC <<<5CV.DE>>>.Further company coverage: <5CV.DE>. (Reporting by Miranda Murray). ((Miranda.Murray@thomsonreuters.com;)).

Dievini Explains Reasons For Changes In Shareholdings In CureVac

Oct 18 (Reuters) - DIEVINI::EXPLAINS REASONS FOR CHANGES IN SHAREHOLDINGS IN CUREVAC DUE TO LEGAL RESTRUCTURING AND OBLIGATIONS UNDER A SHARE PROGRAM.AMENDMENT DOES NOT REFLECT ANY INTENT OF DIEVINI TO EXIT ITS INVESTMENT IN CUREVAC NOR DOES IT CHANGE DIEVINI'S CONFIDENCE IN AND COMMITMENT TO CUREVAC..AS OF TODAY, DIEVINI HAS NO REGISTERED SHARES FOR A SALE.AMENDMENT WAS FILED BY DIEVINI TO COMPLY WITH ITS BENEFICIAL OWNERSHIP REPORTING REQUIREMENTS UNDER UNITED STATES SECURITIES LAWS AND WAS DONE SO WITHOUT INVOLVEMENT OF CUREVAC'S MANAGEMENT..AMENDMENT REPORTED THAT DIEVINI AND/OR OTHER REPORTING PERSONS IN SCHEDULE 13D CONTEMPLATE TO SELL SOME OF THEIR CUREVAC SHARES IN CONNECTION WITH PLANNED DISTRIBUTION BY DIEVINI OF CUREVAC COMMON SHARES TO REPORTING PERSONS.IT AND CERTAIN RELATED PARTIES FILED ON OCTOBER 15, 2021, WITH UNITED STATES SECURITIES AND EXCHANGE COMMISSION AN AMENDMENT TO ITS SCHEDULE 13D WITH RESPECT TO COMMON SHARES OF CUREVAC.AMENDMENT WAS REQUIRED DUE TO IMPLEMENTATION OF HOLDING ENTITIES ON SHAREHOLDER LEVEL OF DIEVINI.AMENDMENT WAS REQUIRED FOR FULFILLMENT OF OBLIGATIONS TO TRANSFERRING SHARES TO CUREVAC WITHIN VIRTUAL SHARES PROGRAM FOR ITS MANAGEMENT BOARD AND SELECTED KEY MEMBERS.

EMA Ends Rolling Review Of CureVac COVID-19 Vaccine After Withdrawal By Co

Oct 12 (Reuters) - European Medicines Agency (EMA)::EMA ENDS ROLLING REVIEW OF CVNCOV COVID-19 VACCINE FOLLOWING WITHDRAWAL BY CUREVAC AG: 12/10/2021.SAYS AT TIME OF CO'S WITHDRAWAL, EMA RECEIVED NON-CLINICAL DATA, DATA FROM ONGOING CLINICAL STUDIES, DATA ON QUALITY, MANUFACTURING PROCESS.SAYS ALTHOUGH EMA WAS SPEEDING UP ITS REVIEW OF DATA, SOME QUESTIONS ABOUT VACCINE'S QUALITY STILL REMAINED TO BE SATISFACTORILY ADDRESSED.SAYS CUREVAC RETAINS RIGHT TO REQUEST ANOTHER ROLLING REVIEW OR SUBMIT A MARKETING AUTHORISATION APPLICATION IN FUTURE.Further company coverage: 5CV.DE. ((Reuters.Briefs@thomsonreuters.com;)).

CureVac's CVnCoV Phase 2B/3 Study Data Published In Preprints With The Lancet

Aug 31 (Reuters) - CUREVAC NV <5CV.DE>::CVNCOV PHASE 2B/3 STUDY DATA PUBLISHED IN PREPRINTS WITH THE LANCET.SIGNIFICANT PROTECTION WAS DEMONSTRATED AMONG PARTICIPANTS IN AGE GROUP OF 18 TO 60, WITH AN EFFICACY OF 53% AGAINST DISEASE OF ANY SEVERITY AND ACROSS ALL 15 IDENTIFIED STRAINS.PROTECTION AGAINST MODERATE TO SEVERE DISEASE FOR THIS AGE GROUP WAS CALCULATED TO BE 77%..IN SAME AGE GROUP, CVNCOV PROVIDED 100% PROTECTION AGAINST HOSPITALIZATION OR DEATH..SUBMISSION OF COMPREHENSIVE CLINICAL DATA PACKAGES TO EMA IS ONGOING AS PART OF ROLLING SUBMISSION INITIATED IN FEBRUARY 2021 AND IS EXPECTED TO BE FINALIZED TOWARD END OF Q3 OF 2021.

Curevac Says Preclinical Data Demonstrates Reduction Of Liver Fibrosis With MRNA Therapeutic

Aug 30 (Reuters) - CUREVAC NV <5CV.DE>::CUREVAC PRECLINICAL DATA DEMONSTRATES SIGNIFICANT REDUCTION OF LIVER FIBROSIS WITH MRNA THERAPEUTIC.FINDINGS IN PRECLINICAL MOUSE MODELS PROVIDE FIRST DIRECT PROOF OF EFFICACY OF HNF4A MRNA THERAPEUTICS IN TREATMENT OF LIVER FIBROSIS AND CIRRHOSIS.

Curevac H1 Revenues At EUR 32.4 Million

Aug 16 (Reuters) - CUREVAC NV <5CV.DE>::CUREVAC ANNOUNCES FINANCIAL RESULTS FOR THE SECOND QUARTER AND FIRST HALF OF 2021 AND PROVIDES BUSINESS UPDATE.REVENUES AMOUNTED TO EUR 22.4 MILLION AND EUR 32.4 MILLION FOR THREE AND SIX MONTHS ENDED JUNE 30 2021.OPERATING LOSS AMOUNTED TO EUR 147.8 MILLION AND EUR 263.7 MILLION FOR THREE AND SIX MONTHS ENDED JUNE 30, 2021, REPRESENTING AN INCREASE OF EUR 144.6 MILLION AND EUR 237.3 MILLION FROM EUR 3.2 MILLION AND EUR 26.4 MILLION FOR SAME PERIODS IN 2020.FINANCIAL RESULTS FOR THREE AND SIX MONTHS ENDED JUNE 30, 2021 WERE A LOSS, ON A NET BASIS, OF EUR 4.4 MILLION AND EUR 0.7 MILLION.PRE-TAX LOSSES WERE EUR 152.2 MILLION AND EUR 264.4 MILLION FOR THREE AND SIX MONTHS ENDED JUNE 30, 2021.

Curevac's CV2CoV Demonstrates Improved Immune Response And Protection In Preclinical Study

Aug 16 (Reuters) - CUREVAC NV <5CV.DE>::SECOND-GENERATION MRNA COVID-19 VACCINE CANDIDATE, CV2COV, DEMONSTRATES IMPROVED IMMUNE RESPONSE AND PROTECTION IN PRECLINICAL STUDY.PRECLINICAL STUDY PROVIDES EVIDENCE FOR STRONGLY IMPROVED IMMUNE RESPONSES WITH SECOND-GENERATION MRNA BACKBONE JOINTLY DEVELOPED BY CUREVAC AND GSK COMPARED TO CUREVAC'S FIRST-GENERATION MRNA BACKBONE.FOLLOWING CURRENT PRECLINICAL DEVELOPMENT OF CV2COV, A PHASE 1 CLINICAL TRIAL IS EXPECTED TO START IN Q4 2021.

Curevac Announces Appointment Of Malte Greune As Chief Operating Officer

June 30 (Reuters) - CureVac NV <5CV.DE>::CUREVAC ANNOUNCES APPOINTMENT OF DR. MALTE GREUNE AS CHIEF OPERATING OFFICER AND TRANSITION OF DR. FLORIAN VON DER MÜLBE TO LEAD ACCELERATED DEVELOPMENT OF RNA PRINTER(R).

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up